Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tropical Disease Voucher Program Would See Another Boost In Cures Bill

Executive Summary

FDA would gain ability to easily change list of diseases eligible for incentive, avoiding need for one-off legislation or rulemaking.

You may also be interested in...



Drug Shortages: Would Sponsors Admit Their Products Are Vulnerable?

US FDA's upcoming drug shortage risk criteria will be made public and sponsors could be asked to find the vulnerable products in their portfolios.

Drug Shortages: Would Sponsors Admit Their Products Are Vulnerable?

US FDA's upcoming drug shortage risk criteria will be made public and sponsors could be asked to find the vulnerable products in their portfolios.

Neglected Tropical Disease Designation Rejected For First Time By US FDA

Pneumocystis pneumonia was determined to not meet criteria for a neglected tropical disease that could win sponsors of a new treatment a priority review voucher; FDA made four other diseases eligible. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel